drugset
Drugs / Dexelvucitabine
last change Apr 2006 re-read 2 minutes ago

Dexelvucitabine

also known as Dexelvucitabina · DFC · DPC 817 · INCB-8721 · Reverset · YZ-817

Small molecule

Developed for
HIV infectious disease
Investigated by
Incyte Corporation · Pharmasset

Trials 2 · a red edge is where a trial was stopped

today NCT00300573 · Ph 2
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00040274 — HIV infectious disease Pharmasset Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00300573 Apr 2006 HIV infectious disease Incyte Corporation Terminated No outcome recorded

Press releases naming this drug 10 releases

DateIssuerRelease
2005-09-28 Incyte Corporation Incyte Announces Outcome of Discussions with FDA Regarding Reverset(TM) incyte.com ↗
2005-08-01 Incyte Corporation Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients incyte.com ↗
2005-07-25 Incyte Corporation Phase IIb Study Shows Reverset(TM) Has Potent Antiviral Activity in Treatment-Experienced HIV Patients Failing Current Treatment Regimen; Findings Presented at the 3rd International AIDS Society Conference incyte.com ↗
2005-07-07 Incyte Corporation Results from Reverset Study 203 Accepted for Late Breaker Presentations at 3rd International AIDS Society Conference in Rio de Janeiro incyte.com ↗
2004-10-31 Incyte Corporation Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients incyte.com ↗
2004-08-04 Incyte Corporation Incyte Announces Second Quarter Financial Results; Provides Update on Reverset and INCB3284, Incyte's Phase I CCR2 Antagonist incyte.com ↗
2004-07-12 Incyte Corporation Results of Phase II Study Presented at the XV International AIDS Conference Demonstrate Reverset Has Potential to Reduce Viral Load in Treatment-Naive and Treatment-Experienced HIV Patients incyte.com ↗
2004-02-11 Incyte Corporation Reverset Data Presented at the 11th Annual Conference on Retroviruses and Opportunistic Infections Demonstrate Potent Antiviral Effects in Treatment-Naive HIV Patients incyte.com ↗
2004-02-11 Incyte Corporation Incyte to Host Conference Call to Discuss Clinical Results From a Phase II Study of Reverset in HIV-Infected Patients incyte.com ↗
2004-02-07 Incyte Corporation Incyte and Pharmasset Announce Preliminary Findings from Phase II Study of Reverset in HIV-Infected Patients; Once-Daily Dosing Results in Significant Reduction in Viral Load incyte.com ↗

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Dexelvucitabine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00300573 ↗
Known as Dexelvucitabina ChEMBL registry synonym — accepted as the source's own label CHEMBL109831 ↗
Known as DFC “Dexelvucitabine (DFC)” NCT00300573 ↗
Known as DPC 817 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00040274 ↗
Known as INCB-8721 ChEMBL registry synonym — accepted as the source's own label CHEMBL109831 ↗
Known as Reverset ChEMBL registry synonym — accepted as the source's own label CHEMBL109831 ↗
Known as YZ-817 ChEMBL registry synonym — accepted as the source's own label CHEMBL109831 ↗
Action Inhibit “nucleoside inhibitor of HIV Reverse Transcriptase” NCT00300573 ↗
Modality Small molecule “investigation nucleoside analog reverse transcriptase inhibitor (NRTI)” NCT00300573 ↗
Route Oral “Single Oral Doses” NCT00040274 ↗